| Literature DB >> 31717981 |
Ruta Prakapaite1,2, Frederic Saab2, Rita Planciuniene3, Vidmantas Petraitis2,4,5, Thomas J Walsh5, Ruta Petraitiene2,5, Rasa Semoskaite6, Rasa Baneviciene6, Lilija Kalediene1, Povilas Kavaliauskas2,4,5.
Abstract
Background andEntities:
Keywords: E. coli; Lithuania; UPEC; serogroups; urinary tract infections
Mesh:
Substances:
Year: 2019 PMID: 31717981 PMCID: PMC6915421 DOI: 10.3390/medicina55110733
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1The age distributions 87 female (F) and 13 male (M) patients with E. coli caused conditions. The median age of female patients was 33 years while 44 years was the median age among male patients with E. coli caused conditions. The whiskers in both boxplots indicate lowest and highest age among females (2–90 years) and males (2–89 years).
Distribution of uropathogenic Escherichia coli (UPEC) resistance patterns among different study groups of the patients with urinary tract manifestations caused by UPEC.
| Study Groups | No. of Isolates (%) | Distribution among Sexes | Frequency of Resistance (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. among F (%) a | No. among M (%) b | AMP | AMC | CXM | CIP | AK | CN | TOB | F | TMP | IPM | MEM | ||
| Total isolates of | 100 (100) | 87 (87) | 13 (13) | 32 (32) | 28 (28) | 43 (43) | 31 (31) | 4 (4) | 3 (3) | 6 (6) | 3 (3) | 16 (16) | 0 (0) | 0 (0) |
|
| 53 (100) | 40 (75.5) | 13 (24.5) | 19 (35.8) | 15 (28.3) | 26 (49.1) | 15 (28.3) | 2 (3.8) | 1 (1.9) | 4 (7.5) | 1 (1.9) | 6 (11.3) | 0 (0) | 0 (0) |
| Cystitis | 10 (18.9) | 9 (90) | 1 (10) | 3 (30) | 1 (10) | 5 (50) | 2 (20) | 1 (10) | 0 (0) | 1 (10) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Endometritis | 2 (3.8) | 2 (100) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Pyelonephritis | 19 (35.8) | 10 (52.6) | 9 (47.4) | 8 (42.1) | 6 (31.6) | 9 (47.4) | 7 (36.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (10.5) | 0 (0) | 0 (0) |
| UTI with urosepsis | 2 (3.8) | 2 (100) | 0 (0) | 1 (50) | 1 (50) | 1 (50) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| UTI c | 20 (37.7) | 17 (85) | 3 (15) | 5 (25) | 7 (35) | 11 (55) | 4 (20) | 1 (5) | 1 (5) | 3 (15) | 1 (5) | 2 (5) | 0 (0) | 0 (0) |
|
| 32 (100) | 32 (100) | 0 (0) | 8 (8) | 8 (8) | 11 (11) | 12 (12) | 1 (1) | 2 (2) | 2 (2) | 0 (0) | 6 (6) | 0 (0) | 0 (0) |
| ASB d | 32 (100) | 32 (100) | 0 (0) | 8 (25) | 8 (25) | 11 (34.4) | 12 (37.5) | 1 (3.1) | 2 (6.3) | 2 (6.3) | 0 (0) | 6 (18.8) | 0 (0) | 0 (0) |
|
| 15 (100) | 15 (100) | 0 (0) | 5 (5) | 5 (5) | 6 (6) | 6 (6) | 1 (1) | 0 (0) | 0 (0) | 2 (2) | 4 (4) | 0 (0) | 0 (0) |
| No clin. data e | 15 (100) | 15 (100) | 0 (0) | 5 (33.3) | 5 (33.3) | 6 (40) | 6 (40) | 1 (6.7) | 0 (0) | 0 (0) | 2 (13.3) | 4 (26.7) | 0 (0) | 0 (0) |
a,b The data in this column indicates the distribution of uropathogenic E. coli isolates recovered from female (F) and male (M) patients; c symptomatic urinary tract infection (UTI) was considered when urine cultures were positive (<106 CFU/mL) for E. coli; d asymptomatic bacteriuria (ASB) was considered when two consecutive urine cultures were positive (≥105 CFU/mL) for E. coli; e isolates recovered with patients with known sex and with no detailed clinical data available. Abbreviations of antibiotics: AMP: ampicillin, AMC: amoxicillin/clavulanate, CXM: cefuroxime, CIP: ciprofloxacin, AK: amikacin, CN: gentamicin, TOB:tobramycin, F: nitrofurantoin, TMP: trimethoprim, IPM: imipenem, MEM: meropenem.
Antimicrobial resistance patterns observed among different serogroups of uropathogenic Escherichia coli (UPEC) isolated from patients with urinary manifestations caused by UPEC.
| No. of Isolates (%) per Group | Distribution of Serogroups among Sex | Frequency of Resistance (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. among F (%) | No. among M (%) | AMP | AMC | CXM | CIP | AK | CN | TOB | F | TMP | IPM | MEM | ||
| Non-UTI associated | 36 (100) | 29 (80.6) | 7 (19.4) | 0 (0) | 16 (44.4) | 35 (97.2) | 1 (2.8) | 2 (5.6) | 0 (0) | 5 (13.9) | 0 (0) | 3 (8.3) | 0 (0) | 0 (0) |
| UTI associated | 64 (100) | 58 (90.3) | 6 (9.4) | 32 (50) | 12 (18.8) | 8 (12.5) | 30 (46.9) | 2 (3.1) | 3 (4.7) | 1 (1.6) | 3 (4.7) | 13 (20.3) | 0 (0) | 0 (0) |
| O2 | 1 (0.6) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| O4 | 4 (6.2) | 3 (75) | 1 (25) | 1 (25) | 1 (25) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (25) | 0 (0) | 0 (0) | 0 (0) |
| O8 | 4 (6.2) | 4 (100) | 0 (0) | 2 (50) | 1 (25) | 0 (0) | 1 (25) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (50) | 0 (0) | 0 (0) |
| O15 | 21 (32.8) | 20 (95.2) | 1 (4.8) | 15 (71.4) | 3 (14.3) | 2 (9.5) | 12 (57.1) | 1 (4.8) | 0 (0) | 1 (4.8) | 1 (4.8) | 4 (19.0) | 0 (0) | 0 (0) |
| O16 | 3 (4.7) | 3 (100) | 0 (0) | 2 (66.7) | 0 (0) | 1 (33.3) | 2 (66.7) | 0 (0) | 1 (33.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| O18 | 4 (6.2) | 3 (75) | 1 (25) | 2 (50) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| O22 | 15 (23.4) | 13 (86.7) | 2 (13.3) | 3 (20) | 2 (13.3) | 1 (6.7) | 9 (60) | 0 (0) | 1 (6.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| O25 | 10 (15.6) | 10 (100) | 0 (0) | 6 (60) | 4 (40) | 2 (20) | 5 (50) | 1 (10) | 0 (0) | 0 (0) | 0 (0) | 4 (40) | 0 (0) | 0 (0) |
| O83 | 2 (3.1) | 1 (50) | 1 (50) | 1 (50) | 1 (50) | 1 (50) | 1 (50) | 0 (0) | 0 (0) | 0 (0) | 1 (50) | 1 (50) | 0 (0) | 0 (0) |
The data in this column indicates the distribution of uropathogenic E. coli isolates recovered from female (F) patients among different study groups; the data in this column indicates the distribution of uropathogenic E. coli isolates recovered from male (M) patients among different study groups; non-UTI associated serogroups are defined as all other possible E. coli O serogroups than the ones that can be detected using Li et al. [19] suggested multiplex PCR reaction; serogroups O1, O6, O7, O21, and O75 were not detected and therefore not included in the table. Abbreviations of antibiotics: AMP: ampicillin, AMC: amoxicillin/clavulanate, CXM: cefuroxime, CIP: ciprofloxacin, AK: amikacin, CN: gentamicin, TOB: tobramycin, F: nitrofurantoin, TMP: trimethoprim, IPM: imipenem, MEM: meropenem.
Figure 2The distribution of E. coli UTI-associated and non-UTI associated serogroups among different clinical conditions. NISG* = non-infectious study group; ISG† = infectious study group; NCR‡ = group with no clinical records available. Abbreviations of legend: ASB = asymptomatic bacteriuria; UTI = clinically confirmed urinary tract infection.
Distribution of uropathogenic Escherichia coli (E. coli) phylogenetic groups A, B1, B2, and D among E. coli isolates obtained from female (F) and male (M) patients with urinary tract manifestations caused by E. coli.
| Phylogenetic Groups | No. among F (%) | No. among M (%) | Total Number of Isolates per Group |
|---|---|---|---|
| Group A | 7 (8.0) | 0 (0) | 7 |
| Group B1 | 14 (16.1) | 4 (30.8) | 18 |
| Group B2 | 43 (49.4) | 7 (53.8) | 50 |
| Group D | 23 (26.4) | 2 (15.4) | 25 |
The data in this column indicates the distribution of uropathogenic E. coli isolates recovered from female (F) patients; the data in this column indicates the distribution of uropathogenic E. coli isolates recovered from male (M) patients.
Figure 3The distribution of E. coli phylogenetic groups (A, B1, B2, and D) among UTI associated serogroups. E. coli serogroups O1, O6, O7, O21, and O75 was not detected so therefore not included in the figure.
Antimicrobial resistance patterns observed among different phylogenetic groups of uropathogenic Escherichia coli (UPEC) isolated from patients in Lithuania.
| Phylogenetic Groups | Antimicrobial Resistance Profiles | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | AMC | CXM | CIP | AK | CN | TOB | F | TMP | IPM | MEM | |
| Group A | 3 (42.9) | 1 (14.3) | 4 (57.1) | 2 (28.6) | 0 (0) | 0 (0) | 1 (14.3) | 0 (0) | 2 (28.6) | 0 (0) | 0 (0) |
| Group B1 | 5 (27.8) | 4 (22.2) | 6 (33.3) | 8 (44.4) | 1 (5.6) | 0 (0) | 1 (5.6) | 0 (0) | 1 (5.6) | 0 (0) | 0 (0) |
| Group B2 | 15 (30) | 11 (22) | 20 (40) | 14 (28) | 1 (2) | 3 (6) | 2 (4) | 2 (4) | 6 (12) | 0 (0) | 0 (0) |
| Group D | 9 (36) | 12 (48) | 13 (52) | 7 (28) | 2 (8) | 0 (0) | 2 (8) | 1 (4) | 7 (28) | 0 (0) | 0 (0) |
AMP: ampicillin, AMC: amoxicillin/clavulanate, CXM: cefuroxime, CIP: ciprofloxacin, AK: amikacin, CN: gentamicin, TOB: tobramycin, F: nitrofurantoin, TMP: trimethoprim, IPM: imipenem, MEM: meropenem.